Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of MBI 226 2.5% and 5.0% Acne Solutions Applied Topically for 6 Weeks to Subjects With Acne Vulgaris

NCT00211523 is registered in ClinicalTrials.gov with BioWest Therapeutics Inc as lead sponsor.

NCT NCT00211523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00211523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of MBI 226 2.5% and 5.0% Acne Solutions Applied Topically for 6 Weeks to Subjects With Acne Vulgaris
Lead sponsor
BioWest Therapeutics Inc
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2000
Completion date
September 30, 2001
Enrollment
75
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acne, acne vulgaris, propionibacterium acnes